## SECTION-1: Identification of the substance / mixture and the company / undertaking

| | |
|---|---|
| **Catalogue Number** | CS-O-30548 |
| **Product Name** | cyproheptadine |
| **CAS No.** | 129-03-3 |
| **Category** | API |
| **Synonyms** | Periactinol |
| **Brand** | Clearsynth Labs Ltd. |
| **Identified uses** | Laboratory Chemicals |
| **Uses advised against** | Not available |
| **Company** | Clearsynth Labs Ltd.<br>Mumbai, India |
| **Emergency Phone #** | +91-22-245045900 |
| **REACH No.** | Not available |

## SECTION 2: Hazards identification

**Disclaimer:** This is sample MSDS. Please email **sales@clearsynth.com** for more details.

### 2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

### 2.2 Label Elements

**Signal Word:** Not available

Not available

**Hazard Statement(s)**

| Code | Statement |
|---|---|
| Not available | Not available |

**Precautionary Statement(s)**

| Code | Statement |
|---|---|
| Not available | Not available |

## SECTION 3: Composition / information on ingredients

3.1 Substance

Component : cyproheptadine
CAS Number : 129-03-3
Molecular Formula : C■■H■■N
Molecular Weight : 287.40
Parent Chemical : Cyproheptadine
Synonyms : Periactinol
Concentration : Not available

## SECTION 4: First aid measures

Not available

## SECTION 5: Firefighting measures

Not available

## SECTION 6: Accidental release measures

Not available

## SECTION-7: Handling and storage

Not available

## SECTION 8: Exposure controls / personal protection

Not available

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

| Test | Result |
|---|---|
| Appearance | White solid |
| IR spectrum | No data available |
| pH | No data available |
| Solubility | In Chloroform |

| Property | Value |
|---|---|
| a) Physical State | No data available |

| Property | Value |
|---|---|
| b) Color | No data available |
| c) Odor | No data available |
| d) pH | No data available |
| e) Vapour Pressure | No data available |
| f) Viscosity | No data available |
| g) Initial Boiling Point and boiling range | No data available |
| h) Melting Point / Freezing Point | No data available |
| i) Auto Ignition Temperature | No data available |
| j) Flash Point | No data available |
| k) Explosion Limit, Lower | No data available |
| l) Explosion Limit, Upper | No data available |
| m) Decomposition Temperature | No data available |
| n) Loss on Drying | No data available |
| o) Relative Density | No data available |
| p) Solubility (in DMSO) | No data available |
| q) Oxidizing Properties | No data available |

## SECTION 10: Stability and reactivity

Not available

## SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Acute toxicity: Unlike most first generation antihistamines, cyproheptadine has been associated with several instances of clinically apparent liver injury. The few cases that have been described had a time to onset of 1 to 6 weeks and a cholestatic or mixed pattern of liver enzyme elevations. Immunoallergic and autoimmune features were not present and most patients recovered rapidly without residual. Acute liver failure due to cyproheptadine has not been described. Likelihood score: C (probable rare cause of clinically apparent liver injury).
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: CYPROHEPTADINE, THE MAIN CONSTITUENT OF THE APPETITE STIMULANT TONIC, MAGNADYN IS A POTENT ANTIHISTAMINE DRUG USED IN THE TREATMENT OF RHINITIS, PRURITUS, URTICARIA, NELSON S SYNDROME & CUSHING S SYNDROME. ITS GENOTOXIC EFFECT WAS

INVESTIGATED ON SWISS ALBINO MOUSE BONE MARROW AND PERIPHERAL BLOOD CELLS THROUGH MICRONUCLEUS ANALYSIS. THE TONIC WAS ADMINISTERED ORALLY IN THREE DIFFERENT DOSES VIZ: 0.1 MG/KG, 0.5 MG/KG AND 2.5 MG/KG OF CYPROHEPTADINE IN 0.15 ML QUANTITY. THE THERAPEUTIC DOSE OF 0.5 MG/KG WAS ADMINISTERED DAILY FOR 45 DAYS. ADEQUATE NEGATIVE AND CYCLOPHOSPHAMIDE (50 MG/KG) TREATED POSITIVE CONTROLS WERE MAINTAINED. THE ANIMALS WERE SACRIFICED AT 24, 48 AND 72 HOURS OF ADMINISTRATION TO ASCERTAIN THE DOSE AND TIME-YIELD EFFECT OF THE DRUG. THE DATA WERE SUBJECTED TO MANN-WHITNEY U-TEST. THE EFFECT OF THE DRUG ON MICRONUCLEUS INDUCTION WAS NOT STATISTICALLY SIGNIFICANT IN BOTH THE TESTS. THERE WAS NO SIGNIFICANT CHANGE IN THE P/N RATIO. THE INCIDENCE OF MICRONUCLEUS IN PCE & NCE OF BOTH THE BONE MARROW AND PERIPHERAL BLOOD CELLS OF THE TREATED ANIMALS WERE STATISTICALLY NONSIGNIFICANT COMPARED TO NEGATIVE CONTROL EVEN AFTER LONG TERM ADMINISTRATION. THE ABOVE STUDY CLEARLY SHOWED THAT CYPROHEPTADINE IS NEITHER CLASTOGENIC NOR MITOCLASTIC IN THE PRESENT TEST SYSTEM.
- Carcinogenicity: No data available.
- Reproductive toxicity: This compound is thought to inhibit the contractile effect of serotinin on smooth muscles by competing with serotonin for its receptor. 41 Pregnancies were treated with 4 to 16 mg and no teratogenic effects were observed.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure
- No data available.

Symptoms related to the physical, chemical and toxicological characteristics
- Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite.

## SECTION 12: Ecological information

Not available

## SECTION 13: Disposal considerations

Not available

## SECTION 14: Transport information

Not available

## SECTION 15: Regulatory information

Not available

## SECTION 16: Other information

Not available

## DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.